GSK1265744 30 mg

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 1

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

CompletedNCT02354937

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2015-07-13End: 2016-11-01Updated: 2020-08-28

Phase 2

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

CompletedNCT01641809

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2012-08-06End: 2019-01-15Updated: 2020-01-30

Related Papers

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

AIDS2021-10-1334 citations

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

JAIDS Journal of Acquired Immune Deficiency Syndromes2020-08-21135 citations

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

Journal of Antimicrobial Chemotherapy2020-03-2711 citations

2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results

Open Forum Infectious Diseases2019-10-018 citations

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

2015-07-19162 citations